Navigation Links
American Heart Association Late-Breaking Clinical Trial Report: New Reversible Antiplatelet Drug no More Effective Than Irreversible One in PCI
Date:11/15/2009

Study highlights:

- A new reversible, intravenous blood thinner did not show superiority over an irreversible one currently approved for use.

- Further investigation of the new anti-clotting drug is warranted.

ORLANDO, Fla., Nov. 15 /PRNewswire-USNewswire/ -- A new, reversible antiplatelet drug did not demonstrate superiority over a current irreversible one in reducing the composite of death, heart attack or ischemia-related revascularization in the 48 hours after angioplasty, researchers reported in a late-breaking clinical trial presentation at the American Heart Association's Scientific Sessions 2009.

The primary endpoint for CHAMPION PCI was not met, but study researchers say they did find some potential benefit of the new drug, cangrelor, that warrants further investigation.

"Our findings combined with those from a companion trial (CHAMPION PLATFORM) suggest that cangrelor reduces the risk of some clinically meaningful ischemic events in patients undergoing percutaneous coronary intervention (PCI)," said Robert A. Harrington, M.D., principal investigator of the study and professor of medicine at Duke University and director of the Duke Clinical Research Institute in Durham NC. "That includes a possible reduction in Q wave infarction and stent thrombosis."

In CHAMPION PCI -- a phase III, multi-national (200 sites, 18 countries), randomized, double-blind, placebo-controlled trial-- researchers tested the hypothesis that cangrelor provides superior or at least non-inferior performance compared to a 600 milligram (mg) dose of clopidogrel during the 48 hours after PCI.

Investigators planned to enroll about 9,000 patients, but the trial was stopped early (May 2009) with 8,820 patients enrolled after an interim review panel concluded it was unlikely to meet its primary endpoint.

Patients were randomly assigned to receive cangrelor or clopidogrel, the FDA-a
'/>"/>

SOURCE American Heart Association
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Viron to Present Data from Phase II Trial at American Heart Association Conference
2. MedImmune Highlights Inflammatory Disease Portfolio at 73rd Annual Meeting of the American College of Rheumatology
3. Topline Results from Phase 2 Clinical Trial of Oral NKTR-118 Presented at 20th American Academy of Pain Management Annual Clinical Meeting (AAPM) in Phoenix
4. Idenix Announces Data Presentations at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
5. Bionovo to Present on Novel Female-Specific Drugs for Obesity at the 20th Annual Meeting of the North American Menopause Society
6. American Capital Receives $182 Million In Proceeds From Sale of Axygen Bioscience
7. American Oriental Bioengineering Announces September Investor Conferences Participation
8. American Scientific Resources To Be Exclusive Seller of Worlds Only FDA Approved Home Needle Destruction Device
9. American Oriental Bioengineerings Jinji Capsules and Boke Nasal Spray Designated Among Chinas Top Branded Drugs of 2009
10. Swedish-American Life Science Summit (SALSS) to Address Major Issues Including Healthcare Reform, Synthetic Biology and Innovative Financing for Biotechs
11. American Oriental Bioengineering Announces Change in Independent Auditor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... 22, 2015 According to a ... & 2D Gel Electrophoresis, Agarose & Polyacrylamide Gel, Capillary ... by Application & by End User - Global Forecast ... expected to reach around $1.98 Billion by 2020 with ... to 2020. Browse 226 ma ...
(Date:5/21/2015)... MO (PRWEB) May 21, 2015 Seventh ... the safety and efficacy of pharmaceutical products and medical ... Maryland Heights, MO 63043, a 50,000 sq. ft. building ... location, to enable strategic growth. Facility renovations will begin ... the new space will occur in September. , ...
(Date:5/21/2015)... , May 21, 2015  The EveryLife Foundation ... (R-UT) and Amy Klobuchar (D-MN) ... Accelerating Cures & Treatments, or OPEN ACT. ... patient advocacy organizations, this bipartisan legislation promises to ... medicines to rare disease patients by incentivizing drug ...
(Date:5/21/2015)... As part of its philanthropic partnership with Banner ... funded a $3.25 million project to relocate and equip ... up-to-date features and technology. , The new pharmacy is ... members will begin moving from the current location to ... , The current pharmacy has been using a ...
Breaking Biology Technology:Electrophoresis Market Worth $1.98 Billion by 2020 2Electrophoresis Market Worth $1.98 Billion by 2020 3Electrophoresis Market Worth $1.98 Billion by 2020 4Seventh Wave Laboratories Purchases Building for Expansion, Upcoming Move 2Seventh Wave Laboratories Purchases Building for Expansion, Upcoming Move 3Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 2Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 3
... - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI ) ... 1/2 clinical trial of OGX-011 in combination with first-line ... cancer (NSCLC). At two years, 30% of patients who ... has previously reported a mature median survival of 14.1 ...
... revolutionary Trusted LASIK Surgeons directory service and website at ... for consumers seeking to improve their vision. What sets ... screening process ensuring that only those who are among ... surgery in the United States are listed. Refractive eye ...
... isn,t your father,s nanocar. It runs cool. , The drivers ... of their creation have the ability to roll at room ... years away, the breakthrough suggests they,ll be easier to adapt ... had to be heated to 200 degrees Celsius before they ...
Cached Biology Technology:OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer 2OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer 3OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer 4OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer 5Baltimore LASIK Surgeon Roy Chuck, MD, PhD of the Wilmer Eye Institute at Johns Hopkins Lists with Trusted LASIK Surgeons 2Baltimore LASIK Surgeon Roy Chuck, MD, PhD of the Wilmer Eye Institute at Johns Hopkins Lists with Trusted LASIK Surgeons 3Baltimore LASIK Surgeon Roy Chuck, MD, PhD of the Wilmer Eye Institute at Johns Hopkins Lists with Trusted LASIK Surgeons 4Baltimore LASIK Surgeon Roy Chuck, MD, PhD of the Wilmer Eye Institute at Johns Hopkins Lists with Trusted LASIK Surgeons 5Baltimore LASIK Surgeon Roy Chuck, MD, PhD of the Wilmer Eye Institute at Johns Hopkins Lists with Trusted LASIK Surgeons 6Baltimore LASIK Surgeon Roy Chuck, MD, PhD of the Wilmer Eye Institute at Johns Hopkins Lists with Trusted LASIK Surgeons 7Baltimore LASIK Surgeon Roy Chuck, MD, PhD of the Wilmer Eye Institute at Johns Hopkins Lists with Trusted LASIK Surgeons 8Rice rolls out new nanocars 2Rice rolls out new nanocars 3
(Date:4/27/2015)... 2015  For more than four decades, AUVSI,s ... the premier worldwide event for the unmanned land, sea, ... event for any local, national, or trade news organization ... markets and current applications of unmanned technologies. The conference ... $48 billion industry, and how it will soon impact ...
(Date:4/20/2015)... , April 20, 2015 Huntington Memorial ... Valley to implant a new miniaturized, wireless monitoring sensor ... is the first and only FDA-approved heart failure monitoring ... admissions when used by physicians to manage heart failure. ... that is implanted in the pulmonary artery (PA) during ...
(Date:4/14/2015)... Conn. , April 14, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... been nominated for the 2015 New York Design Awards ... The Design100, New York City Design Awards are part ... based on over 2,500 ratings from the marketplace, industry ...
Breaking Biology News(10 mins):UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3
... crude oil from the Gulf of Mexico following the Deepwater ... Human Health (TIEHH) at Texas Tech University have reported that ... fertilized mallard duck eggs resulted in a 50 percent mortality ... the oil remained at sea and exposed to weather had ...
... A genetic study focusing on the Central American ... surprising results for a team of Smithsonian scientists involved ... tissue samples collected from 238 wild turtles at 15 ... and Guatemala revealed a "surprising lack" of genetic structure, ...
... Alberta researchers have published a step by step plan to ... crops by developing plants that produce their own fertilizer. ... the energy required to produce nitrogen fertilizers has pushed the ... year. Good says that while they are necessary for high ...
Cached Biology News:Deepwater Horizon crude less toxic to bird eggs after weathering at sea 2Endangered river turtle's genes reveal ancient influence of Maya Indians 2
... pPIC9K and pPIC3.5K vectors carry the kanamycin ... Reagent in Pichia. Spontaneous generation of multiple ... to increased levels of Geneticin Reagent. Pichia ... screened for their level of resistance to ...
Immunogen: Synthetic peptide: R(89) L A F T V D D N P T K P T T R Q R Y(107) Storage: -20 C, Avoid Freeze/Thaw Cycles...
...
...
Biology Products: